ReShape Lifesciences (RSLS) announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6M before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Maxim Group is acting as sole placement agent in connection with the offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape Lifesciences announces EU MDR certification for European, UK portfolio
- ReShape Lifesciences Faces Nasdaq Delisting Notice
- ReShape Lifesciences Announces Equity Distribution Agreement
- ReShape Lifesciences Announces Merger with Vyome Therapeutics
- ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last year